38 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public … and security and physician payment and pricing transparency laws.
The U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity
424B5
MREO
Mereo Biopharma Group Plc
10 Feb 21
Prospectus supplement for primary offering
4:53pm
shares are admitted to trading on AIM is required pursuant to Chapter 5 of the Disclosure Guidance and Transparency Rules of the U.K. Financial Conduct
424B5
MREO
Mereo Biopharma Group Plc
9 Feb 21
Prospectus supplement for primary offering
5:24pm
in the United Kingdom whose shares are admitted to trading on AIM is required pursuant to Chapter 5 of the Disclosure Guidance and Transparency Rules
6-K
EX-99.1
ajfdv6gkg 6t
12 Nov 20
Current report (foreign)
6:15am
424B5
k2lk m2jq
23 Oct 20
Prospectus supplement for primary offering
4:40pm
F-3
qum0f90gj3y 87d
6 Oct 20
Shelf registration (foreign)
4:25pm
F-3
EX-1.2
x1wcp8t0p3fev 2b314n
6 Oct 20
Shelf registration (foreign)
4:25pm
6-K
EX-99.2
rh0ch3v d6rl9
30 Jun 20
Result of Annual General Meeting
4:07pm
6-K
EX-10.1
zxnz7q
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
F-1/A
qjkuw6xskph jidy4k
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
37werpj8u18rt1zc
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
6-K
EX-99.1
gzurf
19 Feb 20
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
9:32am
F-1
ciyl53l4pp1fc5i6cnl
18 Feb 20
Registration statement (foreign)
5:15pm
6-K
EX-99.1
c2jz7dj gwx
10 Feb 20
Current report (foreign)
7:20am
6-K
mji6vgdpd6 8qc
21 Jun 19
Current report (foreign)
11:10am
20-F
EX-4.13.1
63y3hu
29 Apr 19
Annual report (foreign)
4:59pm